Our current studies provides a new and promising anti-cancer approach by using of PL-1/miR-9 nanoparticles and demonstrate miR-9/eIF5A2 as a new potential drug target for future synergic therapy against PDAC. This evidence concerns the gene EIF5A2 and cancer.